title: [Lymphoproliferative syndromes after renal transplantation].
abstract: Following kidney transplantation, lymphoproliferative disorders (LD) are encountered at a frequency of 1%. The onset of these LD is correlated with the degree of immunosuppression. The mortality is elevated (> 50%) especially in late forms. Since 1984 we have performed two hundred and seventeen kidney transplantations. The patients received sequential quadruple-drug immunosuppressive therapy: antilymphocyte globulin (ALG), azathioprine, corticosteroids and cyclosporine. A diagnosis of LD was established in ten patients, four were of early onset (within twelve months of transplantation) and six late (after five to nine years). Rejection occurred in two patients, one of which was steroid resistant requiring ALG. Three LD arose from the graft hilum, four had a voluminous tumor mass with extranodal sites: the graft (1), stomach (2), gingiva (1), meninges (1), and bone marrow (1). Histologically there were eight cases of large-cell B lymphoma, 1 mononucleosis-like LD, and a MALT lymphoma. A search for EBV was positive seven times. Treatment consisted of decreasing immunosuppressive therapy only (1), combined with antiviral treatment (1), or with surgical removal of the graft (3), and/or chemotherapy (5). Nine patients are still alive, in complete remission, graft loss occurred in four cases.
  
  
  CONCLUSIONS
  In our series, we found a high frequency of LD. Despite 4 LD with a voluminous tumor mass and unfavorable histological prognosis requiring chemotherapy, all the LD in our series had a favorable outcome.
authors.affiliation: Service de néphrologie, Centre hospitalier universitaire Dupuytren, Limoges.
authors.forename: Y
authors.initials: Y
authors.lastname: Le Meur
authors.forename: N
authors.initials: N
authors.lastname: Potelune
authors.forename: A
authors.initials: A
authors.lastname: Jaccard
authors.forename: B
authors.initials: B
authors.lastname: Petit
authors.forename: D
authors.initials: D
authors.lastname: Bordessoule
authors.forename: P
authors.initials: P
authors.lastname: Peyronnet
authors.forename: S
authors.initials: S
authors.lastname: Ranger
authors.forename: F
authors.initials: F
authors.lastname: Labrousse
authors.forename: C
authors.initials: C
authors.lastname: Leroux-Robert
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000914:Antibodies, Viral; D000970:Antineoplastic Agents; D000998:Antiviral Agents